ClinicalTrialsFinder
RecruitingPhase 2NCT07230483

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.

Sponsor

Keymed Biosciences Co.Ltd

Enrollment

246 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis (AD)

Summary

This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called CM512 for people with atopic dermatitis (ad). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCM512

CM512 subcutaneous injection

Locations(1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07230483

Related Trials

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

NCT075448621 location

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT0729839523 locations

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT074555782 locations

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT0710548888 locations

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

NCT074536021 location